Lixte Biotechnology Holdings, INC Schedule 13G passive stakes
Filed when an investor crosses five percent without intending to seek control — the passive counterpart to a 13D.
NASDAQ
Vanguard Capital Management has reported beneficial ownership of 5.02% of Lixte Biotechnology Holdings Inc. common stock as of June 30, 2026.
NASDAQ
Strategic EP, LLC and Alexander Chase Deitch have filed a Schedule 13G disclosing a 5.1% beneficial ownership stake in Lixte Biotechnology Holdings, Inc.
NASDAQ
Orca Capital AG, a German entity, has disclosed a 4.5% beneficial ownership stake in Lixte Biotechnology Holdings, Inc., holding 120,012 shares of common stock.
NASDAQ
SCHEDULE 13G: Intracoastal Capital and Affiliates Disclose 4.99% Stake in Lixte Biotechnology Holdings
Intracoastal Capital LLC, along with Mitchell P. Kopin and Daniel B. Asher, has disclosed a beneficial ownership of 4.99% in Lixte Biotechnology Holdings, Inc. common stock.
NASDAQ
Orca Capital AG has filed a Schedule 13G, revealing a passive beneficial ownership of 8.1% in Lixte Biotechnology Holdings, Inc., comprising 217,392 shares.